|
A.P. Pharma’s primary near-term objective is to successfully file the NDA for APF530, followed by executing the necessary actions to obtain approval of that product from the FDA. Longer-term, the Company intends to become a leading specialty pharmaceutical company focused on improving the effectiveness of existing pharmaceuticals using its proprietary drug delivery technologies. Key elements of the Company's strategy include:
Maximize the value of our lead product, APF530. A.P. Pharma believes that establishing a partnership with a pharmaceutical company for the commercialization of APF530 will maximize the value of APF530 for its shareholders.
Enter into strategic partnerships. The Company believes that selective partnering of its future product development programs can enhance the success of the Company’s product development and commercialization efforts, and enable diversification of its product portfolio by having partners fund the major portion of its late stage clinical trials. Additionally, such partnering will enable A.P. Pharma to leverage the sales capabilities of the Company’s partners to commercialize its products.
Minimize product development risk and time-to-market. A.P. Pharma is applying its proprietary drug delivery technologies to improve the effectiveness of approved pharmaceutical products. By using the Company’s technologies to administer drugs for which clinical efficacy and safety data are available, A.P. Pharma will reduce the cost and development risk inherent in traditional pharmaceutical product development.
Expand product pipeline. A.P. Pharma plans to expand its product pipeline by leveraging their existing technology. The Company intends to develop new products based on the Company’s Biochronomer™ polymer-based drug delivery technology. A.P. Pharma’s research has indicated that the Biochronomer technology has potential applications across a range of therapeutic areas, including prevention of nausea, pain management, control of inflammation and treatment of ophthalmic diseases. With further work on its technology platforms, A.P. Pharma may be able to develop products that deliver proteins, peptides, soluble RNA (sRNA) and RNA interference (RNAi).
|
